-
Transarterial Chemoembolization (TACE) Combined with Camrelizumab and Rivoceranib Versus TACE Alone in Unresectable Hepatocellular Carcinoma
CARES-005 was a multicenter, open-label, randomized phase 2 study enrolling 200 patients with unresectable HCC. Patients were assigned to either TACE plus camrelizumab (200 mg IV, Q3W) and rivoceranib (250…
-
Voices from China at ESMO Asia: Dr. Rongbo Lin’s Team Reveals a Novel Treatment for Refractory Cancer Pain with Promising Potential to Improve Patient
________________________________________ Study Overview This study employed a standard 3+3 dose-escalation design, enrolling patients with a Numerical Rating Scale (NRS) pain score of 3–6 who reported unsatisfactory pain control despite 1–2…
-
Unraveling HLA Class I Expression in Breast Cancer: A Step Towards Precision Immunotherapy
At the San Antonio Breast Cancer Symposium 2024, Dr. Paula Ines Gonzalez Ericsson presented important research on HLA class I expression in breast cancer and its implications for immunotherapy response. Her…
-
Dr. Charles Geyer, Jr.’s Contributions to Advancing Triple-Negative Breast Cancer Research
At the San Antonio Breast Cancer Symposium 2024, Dr. Charles Geyer, Jr. presented important research focused on improving treatment strategies for triple-negative breast cancer (TNBC). His work continues to drive…
-
Maria Vittoria Dieci at SABCS 2024: Advancing Immunotherapy in TNBC
At the San Antonio Breast Cancer Symposium 2024, Maria Vittoria Dieci presented key findings from the A-BRAVE trial, shedding light on the role of avelumab in high-risk triple-negative breast cancer…
-
CheckMate 649: Five-Year Follow-Up Reinforces Nivolumab + Chemotherapy as Standard First-Line Treatment
The five-year follow-up data from CheckMate 649, presented at the 2025 ASCO Gastrointestinal Cancers Symposium, confirms the long-term survival benefits of nivolumab plus chemotherapy in advanced gastric, gastroesophageal junction, and…
-
Advancing First-Line Therapy for Unresectable Hepatocellular Carcinoma (uHCC): CheckMate 9DW Results
The phase 3 CheckMate 9DW trial, presented at ASCO24, brings promising results for nivolumab (NIVO) + ipilimumab (IPI) as a potential new standard of care in first-line treatment for unresectable…
-
Who Benefits Most from Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer?
A systematic review and meta-analysis, published in The Lancet Oncology, provides new insights into which patients benefit most from adding docetaxel to androgen deprivation therapy (ADT). The data, pooled from…
Connecting Medical Expertise through Media